SCHEMBL1359362

SCHEMBL1359362

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc2c(-c3ccc(C(N)=O)cc3)coc12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.40
TYK2 P29597 1/20 0.35
CYP3A4 P08684 3/20 0.35
MKNK1 Q9BUB5 2/20 0.33
MKNK2 Q9HBH9 2/20 0.33
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
CREBBP Q92793 1/20 0.33
CAMKK2 Q96RR4 3/20 0.33
ABL1 P00519 1/20 0.32
DHODH Q02127 1/20 0.32
MAP3K11 Q16584 1/20 0.32
POLB P06746 2/20 0.32
MEN1 O00255 1/20 0.32
BLM P54132 1/20 0.32
KMT2A Q03164 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
ATR Q13535 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359206 0.91 BRD4 (0.39) GSK3BCYP3A4CREBBPABL1DHODH
SCHEMBL1359880 0.88 CYP3A4 (0.36) CYP3A4
SCHEMBL1358251 0.86 CYP3A4 (0.38) CYP3A4POLBMEN1KMT2AMAPT
SCHEMBL1358345 0.85 CYP3A4 (0.41) CYP3A4POLBMEN1BLMKMT2A
SCHEMBL1358776 0.84 CYP3A4 (0.39) CYP3A4ABL1MEN1KMT2AMAPT
SCHEMBL1359278 0.83 PDE3B (0.37) CYP3A4CREBBPABL1MAP3K11ATR
SCHEMBL1359884 0.83 CYP3A4 (0.35) CYP3A4
SCHEMBL1359548 0.82 BRAF (0.36) CYP3A4
SCHEMBL1359830 0.81 ALOX5AP (0.37) CYP3A4ABL1
SCHEMBL1358305 0.80 CYP3A4 (0.55) CYP3A4IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS GSK3B 2357/4885TYK2 4037/4885CYP3A4 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.